Sensorion, a clincial-stage biotech working on novel therapies for hearing loss disorders, has appointed Nora Yang, Ph.D. as Chief Scientific Officer (CSO).
Dr. Yang has 20 years of executive and scientific leadership experience in pharmaceutical, biotech, venture capital industries, academia and government, building up a unique blend of expertise in biomedical research, drug development, regulatory sciences, finance, portfolio and pharmaceutical projects management.
Dr. Yang is a leader in gene and cell therapies for treating monogenic rare diseases, including expertise in developing three clinical stage gene therapies to treat monogenic rare disorders. She is an internationally recognized expert and leader in rare and ultra-rare disease translational research with deep domain knowledge and broad network in orphan drug development.
She joins Sensorion from Stratify Therapeutics, LLC, where she was Co-Founder and CSO, having previously held senior roles at the U.S. National Institutes of Health (NIH), Amgen Inc., and Eli Lilly & Co. In particular, she was instrumental in the development of clinical stage gene therapies to treat monogenic diseases.
In her new role, Nora Yang will be based in the US and will lead the preclinical organization at Sensorion Research Laboratories in Montpellier, France. She will also spearhead the development of collaborations between fundamental and clinical research, including working with Sensorion’s partner, Institut Pasteur.
Dr. Yang holds a Ph.D. in Chemistry, from the University of California, San Diego and the Gene Expression Laboratory at the Salk Institute for Biological Studies. Dr. Yang also holds a master's degree in Management from Stanford Graduate School of Business.